ThinkrBelle offers pharma and healthtech companies advisory services and connections to assist with navigating the commercialization journey.

Description

ThinkrBelle is a PharmaTech boutique advisory firm that bridges Canada’s healthtech companies to global pharma. ThinkerBelle focuses on solving pharma’s most critical problems by facilitating tech/SaaS collaborations between pharma and start-ups. Its advisors act as “APIs” bringing innovations for a pharma company’s post-launch phase (ie. in medical affairs, sales, marketing, market access).

The ThinkrBelle team helps navigate the path for Tech companies trying to break into a very complex B2B landscape, in turn reducing barriers for pharma to deploy groundbreaking advancements in Canada and beyond.

ThinkrBelle’s agile advisory model is rooted in deep, lived experiences from both the biopharma and healthtech, and digital-tech sectors. This enables the firm to catalyze productive paid engagements for tech start-ups within pharma’s commercial use cases, enabling operational efficiencies and expediting deployment of human-first healthtech life-altering solutions for patients.

Contact the team at Innovation Factory to access the perks and services offered to clients by ThinkrBelle.

Get connected with ThinkrBelle

ThinkrBelle

Category

Quick Facts

  • Advisors with both tech and pharma experience.
  • Deep understanding of  pharma’s industry pain points
  • Ability to  work as fractional team members 
  • Focused on the post-launch phase in pharma
  • Deep networks within global pharma corporations
  • Access to leaders in the pharma sector
Synapse Life Science Pitch Competition applications open. Apply by November 10, 2024

Applications for the 2025 Synapse Competition are open!

The Synapse Life Science Competition combines the ideas and research of life science innovators with the intellect and strategy of students. Finalists receive training, mentorship, a $2,000 grant and a chance to pitch and compete for BIG cash prizes!

Applications close on November 10, 2024.